About Proton-coupled amino acid transporter 2
Proton-coupled amino acid transporter 2 (SLC36A2) is a protein
from Homo sapiens identified by UniProt accession
Q495M3, 483 residues long.
MolForge cross-references it against 0 known binders and
32 disease associations.
Target properties
| Protein name | Proton-coupled amino acid transporter 2 |
| UniProt accession | Q495M3 |
| Gene | SLC36A2 |
| Organism | Homo sapiens |
| Length | 483 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (32)
Diseases linked to this target (Open Targets).
- iminoglycinuria · score 0.49
- Sensorineural hearing impairment · score 0.37
- pyroglutamine measurement · score 0.24
- Hyperglycinuria · score 0.23
- adolescent idiopathic scoliosis · score 0.06
- basophil count · score 0.03
- infection · score 0.03
- infect · score 0.03
- basophil percentage of leukocytes · score 0.02
- bronchopulmonary dysplasia · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q495M3-F1 | alphafold | PREDICTED | 84.05 | — |
Amino-acid sequence (483 residues)
MSVTKSTEGP QGAVAIKLDL MSPPESAKKL ENKDSTFLDE SPSESAGLKK TKGITVFQAL IHLVKGNMGT GILGLPLAVK NAGILMGPLS LLVMGFIACH CMHILVKCAQ RFCKRLNKPF MDYGDTVMHG LEANPNAWLQ NHAHWGRHIV SFFLIITQLG FCCVYIVFLA DNLKQVVEAV NSTTNNCYSN ETVILTPTMD SRLYMLSFLP FLVLLVLIRN LRILTIFSML ANISMLVSLV IIIQYITQEI PDPSRLPLVA SWKTYPLFFG TAIFSFESIG VVLPLENKMK NARHFPAILS LGMSIVTSLY IGMAALGYLR FGDDIKASIS LNLPNCWLYQ SVKLLYIAGI LCTYALQFYV PAEIIIPFAI SRVSTRWALP LDLSIRLVMV CLTCLLAILI PRLDLVISLV GSVSGTALAL IIPPLLEVTT FYSEGMSPLT IFKDALISIL GFVGFVVGTY QALDELLKSE DSHPFSNSTT FVR
Explore Proton-coupled amino acid transporter 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets